Aquestive Therapeutics, Inc.
$4.84
The Read: Aquestive's stock has historically surged on clear regulatory timelines and strong earnings beats, notably rallying over 65% when reaffirming the Anaphylm NDA resubmission and securing debt refinancing, but faced muted or mixed reactions amid class-action lawsuits and revenue misses.
Price
Overlays
Panel
AQST
Hover to view data
No Data